Growth at Norwich Pharmaceuticals

NORWICH – Norwich Pharmaceuticals has entered a new phase in its growth as a pharmaceutical manufacturer. In July of last year, they reported the acquisition of Norwich Pharmaceuticals by AFI Partners. AFI Partners has now announced the creation of a “sister” company to Norwich Pharmaceuticals, to be named “Alvogen.”



Doug Drysdale has been appointed CEO of both Alvogen and Norwich Pharmaceuticals. There is no change in local management, with Chris Calhoun remaining President of Norwich Pharmaceuticals. Alvogen will sit alongside Norwich Pharmaceuticals in the corporate structure, but will be its own legally incorporated entity.


There's more to this story! You're only seeing 28% of the story. Subscribe now to get immediate access to the rest of the story as well as our whole online offering.

Today's Other Stories



© 2014 Snyder Communications/The Evening Sun
29 Lackawanna Avenue, Norwich, NY 13815 - (607) 334-3276
We're on Facebook